NVO
NYSE · Healthcare
Novo Nordisk A/S
$47.26
+1.29 (+2.81%)
NVO News30 articles
Lilly's Q2 Growth Hinges on Mounjaro, Zepbound as Sales Projection Leans Heavily on Weight-Loss Franchise
Eli Lilly (LLY) is set to report Q2 earnings Wednesday, with Mounjaro and Zepbound expected to contribute 98% of revenue growth. Pre-market shares rose 2.2% after a five-day slide.
Novo Nordisk Slips 4% as Profit Beat Fails to Quell Wegovy Worries
Novo Nordisk shares dropped 4% in Copenhagen after Q2 profit beat estimates, but concerns over Wegovy and pipeline setbacks weighed on sentiment.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Novo Nordisk ADR Slides Despite Strong Q2, Danish Shares Await Catch-Up
Novo Nordisk's ADR dropped 6.8% despite Q2 earnings surpassing forecasts, as investors weigh pipeline impairments and competitive pressures.
Hims & Hers Stock Rebounds 11% Ahead of Q2 Earnings Test
Hims & Hers shares surged 11% before earnings, erasing FTC-related losses. The focus now shifts to margin recovery and Eucalyptus integration.
Novo Nordisk Shares Plunge 9% as ZEUS Trial Fails to Show Cardiovascular Benefit
Novo Nordisk shares fell sharply after ZEUS trial data showed no significant cardiovascular benefit, wiping out $20.5 billion in market cap and underscoring heavy reliance on GLP-1 franchise.
Altimmune Shares Jump on Positive Alcohol-Use Disorder Trial Data, Warrant Exercise in Focus
Altimmune shares surged following positive Phase 2 results for pemvidutide in alcohol-use disorder, with the stock price triggering $225 million in warrants.
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
Eli Lilly's $50 Obesity Drug Strategy: Volume vs. Price
Eli Lilly's stock hovers near record highs as a new Medicare program offers $50/month access to its obesity drugs. First-quarter revenue surged 56%, but lower realized prices trimmed growth.
Novo Nordisk B Shares Lag OMXC25 as Low Volume Clouds Rally Ahead of H1 Report
Novo Nordisk B shares rose 2.8% last week but lagged the broader Danish market. Low volume raises caution ahead of August H1 results.
Novo Nordisk Shares Decline as Medicare Caps Wegovy Pricing
Novo Nordisk shares slipped 1.36% as Medicare's new GLP-1 Bridge program caps Wegovy pricing at $245 monthly net, limiting revenue upside despite strong prescription growth.
Microsoft Stock Rises on $2.5B AI Unit Launch, Outpaces Nasdaq
Microsoft shares climbed 1.62% to $390.49, boosted by its $2.5 billion Frontier AI unit, while the Nasdaq fell 0.80%. The gain added $46.1 billion in market value.
Hims & Hers Shares Surge on Canaccord Upgrade Amid GLP-1 Shift
Hims & Hers shares climbed 9.5% to $37.97 after Canaccord Genuity raised its target to $40, reflecting a 25% bump. The company's GLP-1 strategy and Medicare's new Bridge program are reshaping the weight-loss drug market.
Pfizer Gains on China GLP-1 News, but Dividend Focus Limits Upside
Pfizer shares edged up 0.4% after its GLP-1 drug cleared a China insurance review, but the stock trails the S&P 500 as investors weigh dividend yield against growth prospects.
Novo Nordisk B Shares Surge on South African Court Ruling Against Compounder
Novo Nordisk B shares surged 9.9% in three sessions after a South African court halted iDexis from supplying compounded semaglutide, potentially shifting demand to Novo.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
Novo Nordisk Shares Rally as Healthcare Sector Lifts OMXC25
Novo Nordisk B shares rose 5% to 294.4 Danish crowns, leading the OMXC25 higher as healthcare stocks gained. The rally came amid a cyber incident and ongoing competition with Eli Lilly in oral obesity drugs.
Pfizer CFO Departure Raises Growth Strategy Questions, Stock Slips 3%
Pfizer shares slid 3.2% after announcing CFO Dave Denton's departure, intensifying investor scrutiny of the company's 2026 guidance and obesity drug strategy.
Hims & Hers Health Surges on Weight-Loss Drug Strategy Optimism
Hims & Hers Health (HIMS) shares rallied 6.6% to $28.98 on heavy volume, bucking a tech selloff, as investors refocus on the company's weight-loss drug scaling potential after a challenging quarter.
Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi
Pfizer shares fell premarket despite FDA approval for hemophilia drug Hympavzi, as investors focus on slower obesity drug progress and pipeline challenges.
Novo Nordisk Shares Slide 4% Despite Wegovy Pill Prescriptions Surpassing 3 Million
Novo Nordisk shares dropped over 4% despite the Wegovy pill hitting 3 million U.S. prescriptions, as investors weighed profit margins against fierce competition from Eli Lilly and AstraZeneca.
Eli Lilly Faces Market Test After Retatrutide Shows Broad Health Benefits
Eli Lilly's new obesity drug retatrutide showed 28.3% weight loss and improvements in sleep apnea and knee pain. The stock faces a key test Monday amid competing data from rivals.
Eli Lilly Hits Record Close on Retatrutide Data; Market Awaits Monday
Eli Lilly shares closed at a record $1,131.42 Friday after retatrutide data showed significant reductions in sleep apnea and knee osteoarthritis pain. Investors eye Monday's trade for market reaction.
Veru Stock Soars on Novo Nordisk Supply Deal for Obesity Trial
Veru shares jumped 88% to $4.23 after Novo Nordisk agreed to supply Wegovy for Veru's Phase 2b obesity trial. Analysts see it as a validation, but risks remain with trial endpoints and a 60-day exit clause.
Veru Stock Surges on Novo Nordisk Obesity Trial Collaboration
Veru shares surged 112% to $4.78 after Novo Nordisk will provide Wegovy for Veru's Phase 2b obesity trial. Analysts kept $24-$25 targets, but Veru warned of trial risks and reimbursement challenges.
Hims Completes $1.15B Eucalyptus Acquisition, Shares Dip Slightly
Hims & Hers shares fell 0.9% after completing the $1.15 billion Eucalyptus acquisition, gaining 850,000 customers and international reach, but facing execution risks and U.S. weight-loss drug plan shifts.
Lilly Expands Vaccine Portfolio with $3.83B Triple Acquisition
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Company for up to $3.83B, gaining vaccine candidates for shingles, staph, and Epstein-Barr virus. Shares rose 5%.
CPI Surge and Oil Spike End Wall Street's Record Rally
U.S. stocks retreated Tuesday after a hotter-than-expected April CPI report and a surge in oil prices to $107.72 halted Wall Street's record run. Markets now price zero Fed rate cuts in 2026.
Hims & Hers Stock Plunges on Q1 Loss, Weight-Loss Strategy Shift
Hims & Hers shares dropped 10% on a surprise Q1 net loss and revenue miss. The company raised its 2026 sales forecast but cut profit outlook amid a costly shift to branded weight-loss drugs.